Palivizumab is a humanized monoclonal antibody used for the prevention of respiratory syncytial virus (RSV) infection in pediatric patients; it works by binding to the RSV fusion protein on the viral surface, thereby inhibiting membrane fusion and preventing cell-to-cell fusion of RSV-infected cells.